|Title:||Method of producing FR901228|
|Abstract:|| Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion ##STR00001##|
|Inventor(s):|| Ueda; Satoshi (Osaka, JP), Watamoto; Yoko (Osaka, JP), Tsuboi; Masaru (Osaka, JP), Kanda; Munekazu (Osaka, JP), Higaki; Tomoji (Osaka, JP), Matsuda; Mitsunori (Osaka, JP) |
|Assignee:|| Astellas Pharma, Inc. (Tokyo, JP) |
|Filing Date:||Aug 22, 2001|
|Claims:||1. A method of producing FR901228 which comprises culturing a producing strain for FR901228 represented by the following formula: ##STR00003## in a medium added with at least one amino acid selected from the group consisting of L-arginine, L-histidine, L-cystine and L-cysteine or salt thereon. |
2. A method according to claim 1, wherein the amino acid is L-cysteine.
3. A method according to claim 1, wherein the amino acid is added in a concentration of 2 to 30 mM with respect to a medium in a volume of 1 liter.
4. A method according to claim 2, wherein the amino acid is added in a concentration of 2 to 30 mM with respect to a medium in a volume of 1 liter.